Search results for "Acute"

showing 10 items of 2516 documents

The effect of the thrombolytic therapy on the early rehabilitation of patients with acute ischemic stroke – study report

2020

Introduction. r-TPA intravenous thrombolytic therapy is a big step in acute management of ischemic stroke (IS) but is burdened by a small therapeutic window (max. 4.5 hours) that restricts patient access. NIH stroke scale (NIHSS) is the largest worldwide tool used by doctors in order to objectively quantify the severity of neurological impairment in acute IS, in the initial stage as well as in the subsequent stages. Material and method. The aim of this paper is to present the results of an observational, prospective, analytical study on a number of 110 patients with acute IS, hospitalized within two months in the Neurology Clinic of Sibiu (19 patients with thrombolytic therapy applied, 91 p…

medicine.medical_specialtynih stroke scalebusiness.industryneurological patternlcsh:RM1-950General Medicine030204 cardiovascular system & hematologyearly rehabilitation03 medical and health scienceslcsh:Therapeutics. Pharmacology0302 clinical medicineStudy reportEmergency medicineischemic strokemedicinebusinessEarly rehabilitationAcute ischemic stroke030217 neurology & neurosurgeryBalneo Research Journal
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

Stress Hyperglycemia as Predictive Factor of Recurrence in Children with Febrile Seizures

2020

Stress hyperglycemia and hyperlactatemia are commonly referred to as markers of stress severity and poor outcome in children with severe acute illness or febrile seizures. Our prospective study aimed to explore the risk factors for stress hyperglycemia and the predictive value of stress hyperglycemia for febrile seizure recurrence. We evaluated as risk factors for blood glucose level, serum lactate, acid&ndash

medicine.medical_specialtyrecurrenceendocrine system diseasesContext (language use)030204 cardiovascular system & hematologyStress hyperglycemiaGastroenterologyhyperlactatemiaArticlelcsh:RC321-57103 medical and health sciences0302 clinical medicineInterquartile rangeFebrile seizureInternal medicinemedicineAcute stress reactionProspective cohort studylcsh:Neurosciences. Biological psychiatry. Neuropsychiatrystress hyperglycemiabusiness.industryGeneral Neurosciencenutritional and metabolic diseasesmedicine.diseasemetabolic statusPredictive factorHyperlactatemiafebrile seizurebusiness030217 neurology & neurosurgeryBrain Sciences
researchProduct

Diagnostic Accuracy of a New Antigen Test for SARS-CoV-2 Detection

2021

Background and aims: Quick and reliable diagnostic tools play an important role in controlling the spread of the SARS-Cov-2 pandemic. The aim of this study was to evaluate the diagnostic accuracy of a new cyto-salivary antigen test aimed at detecting the presence of antigens for SARS-CoV-2, as compared by the gold standard RT-PCR and a lateral flow test. Methods: A total of 433 healthy volunteers were enrolled in the study and the sensitivity and specificity of the new cyto-salivary antigen test were calculated, as compared to the RT-PCR nasopharyngeal swab and to the lateral flow test. Results: A total of 433 samples were collected and tested at the Mediterranean Fair in Palermo from Febru…

medicine.medical_specialtyrespiratory disease COVID-19Coronavirus disease 2019 (COVID-19)Health Toxicology and MutagenesisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)cyto-salivary testRT-PCRDiagnostic accuracyImmunologic TestsGastroenterologyAsymptomaticSensitivity and SpecificityArticlelateral flow testLateral flow test03 medical and health sciences0302 clinical medicineAntigenInternal medicinemedicineHumansImmunologic Test030212 general & internal medicinePandemics030304 developmental biology0303 health sciencesbusiness.industrySARS-CoV-2Public Health Environmental and Occupational HealthRCOVID-19Gold standard (test)Antigen testSARS-CoV-2.MedicineELISAmedicine.symptombusinessHumanInternational Journal of Environmental Research and Public Health
researchProduct

Post-infectious myocardial Infarction: Does percutaneous coronary intervention improve outcomes? A propensity-score matched analysis

2020

Acute infection is a frequent trigger of myocardial infarction (MI). However, whether percutaneous coronary intervention (PCI) improves post-infectious MI prognosis is a major but unsolved issue. In this prospective multicenter study from coronary care units, we performed propensity score-matched analysis to compare outcomes in patients with and without PCI for post-infectious MI with angiography-proven significant coronary stenosis (&gt

medicine.medical_specialtyrespiratory tract infectionmedicine.medical_treatmentlcsh:Medicine030204 cardiovascular system & hematologyArticletype 2 myocardial infarctionCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicinemedicinepneumonia030212 general & internal medicinecardiovascular diseasesMyocardial infarctionProspective cohort studycoronary care unitbusiness.industrylcsh:Rpercutaneous coronary interventionPercutaneous coronary interventionGeneral Medicinemedicine.diseasemortalityStenosismyocardial infarctionsurgical procedures operativeConventional PCIPropensity score matchingCoronary care unitoutcomeCardiologyObservational studyCardiology and Cardiovascular Medicinebusinessacute infectionArchives of Cardiovascular Diseases Supplements
researchProduct

Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.

2021

Being a "trending" unique treatment for moderate-to-severe acne, isotretinoin (13-cis retinoic acid) (ISO) is currently considered by experts the first line treatment even for mild acne, unless there is an absolute contraindication. ISO was identified, among other retinoids, to inhibit SARS-CoV-2 replication in Vero E6 cells. Shoemark et al.1.

medicine.medical_specialtyskinCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Retinoic acidDermatologyProtective Agents030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCOVID‐19Acne VulgarismedicineHumansskin and connective tissue diseasesLetters to the EditorIsotretinoinContraindicationAcnebusiness.industrySARS-CoV-2COVID-19isotretinoinmedicine.diseaseDermatologyFirst line treatmentchemistry030220 oncology & carcinogenesisVero cellbusinessmedicine.drugDermatologistsJournal of cosmetic dermatology
researchProduct

Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell…

2021

The potential role of active CMV infection in promoting acute Graft-versus-Host Disease (aGvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a matter of debate. We further addressed this issue conducting a retrospective, observational, multicenter study of 632 patients subjected to allogeneic peripheral blood HSCT at 20 Spanish centers. Monitoring of CMV DNA load in plasma or whole blood was performed by real-time PCR assays. Cumulative incidence of CMV DNAemia was 48.9% (95% CI, 45%-52.9%), of any grade aGvHD, 45.6; 95% (CI, 41.3%-50.1%), and of grade II-IV aGvHD, 30.7 (95% CI, 24.9%-36.4%). Overall, development of CMV DNAemia at any level resulted in an increa…

medicine.medical_specialtyversus&#8208medicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusGraft vs Host DiseaseDiseaseHematopoietic stem cell transplantationCMV DNAemia030230 surgeryGastroenterologyCMV DNAemia acute graft-versus-host disease allogeneic hematopoietic stem cell transplantation cytomegalovirus (CMV)Cell therapy03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesMedicineHumansCumulative incidenceallogeneic hematopoietic stem cell transplantationWhole bloodRetrospective StudiesTransplantationhost diseasePeripheral Blood Stem Cell Transplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesmedicine.diseaseacute graft&#8208TransplantationHaematopoiesisInfectious Diseasessurgical procedures operativecytomegalovirus (CMV)030211 gastroenterology & hepatologybusinessTransplant infectious disease : an official journal of the Transplantation SocietyREFERENCES
researchProduct

Ultra-low contrast coronary angiography and zero-contrast percutaneous coronary intervention for prevention of contrast-induced nephropathy: step-by-…

2019

Contrast-induced nephropathy is a serious complication after intravascular administration of iodinated contrast media and is associated with numerous adverse outcomes. Its prevalence is particularly high in patients with multiple comorbidities who undergo coronary angiography and percutaneous coronary intervention (PCI). Currently, the only effective method to prevent contrast-induced kidney injury is adequate hydration and a reduction of contrast volume during the intervention. Recently, new approaches aiming to minimize contrast usage have been proposed, i.e., ultra-low contrast angiography and zero-contrast PCI. However, neither tutorials for these techniques nor reviews of their outcome…

medicine.medical_specialtyzero-contrast percutaneous coronary interventionmedia_common.quotation_subjectmedicine.medical_treatmentContrast-induced nephropathylcsh:Medicine030204 cardiovascular system & hematologyNephropathyrenal insufficiency03 medical and health sciences0302 clinical medicineIntervention (counseling)medicineContrast (vision)030212 general & internal medicineIntensive care medicinemedia_commonReview Paperbusiness.industrylcsh:RAcute kidney injuryPercutaneous coronary interventionmedicine.diseaseacute kidney injurycontrast-induced nephropathyConventional PCICardiology and Cardiovascular MedicinebusinessComplicationchronic kidney diseaseAdvances in Interventional Cardiology
researchProduct

Zero-contrast percutaneous coronary interventions to preserve kidney function in patients with severe renal impairment and hemodialysis subjects

2019

Introduction Zero-contrast percutaneous coronary intervention (zero-PCI) is a new method for prevention of contrast-induced acute kidney injury (AKI) in patients with chronic kidney disease (CKD). However, evidence for its feasibility, safety and clinical utility is limited to reports of single cases or series of patients. Aim To present outcomes of zero-PCI in patients with severe CKD, including hemodialysis subjects, who were treated with this procedure in order to preserve their renal function. Material and methods Twenty-nine zero-PCIs were performed, mostly as a staged procedure, in 20 patients with advanced CKD. In this group, 4 patients were treated with hemodialysis but presented pr…

medicine.medical_specialtyzero-contrast percutaneous coronary interventionmedicine.medical_treatmentContrast-induced nephropathylcsh:MedicineRenal function030204 cardiovascular system & hematologyRevascularizationurologic and male genital diseasesrenal insufficiency03 medical and health sciences0302 clinical medicine0502 economics and businessmedicineRenal replacement therapyOriginal Paperbusiness.industrylcsh:R05 social sciencesAcute kidney injuryPercutaneous coronary interventionmedicine.diseaseSurgeryacute kidney injurycontrast-induced nephropathy050211 marketingHemodialysisCardiology and Cardiovascular MedicinebusinessKidney diseasePostępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology
researchProduct

INFLAMMATORY CYTOKINES IN ACUTE ISCHEMIC STROKE.

2008

Three major cytokines, namely, tumor necrosis factor (TNF-alpha), interleukin (IL)-1, and IL-6 are produced by cultured brain cells after various stimuli such as ischemia. Neurones, astrocytes, microglia and oligodendrocytes can produce inflammatory mediators, and cytokine receptors are expressed constitutionally throughout the Central Nervous System (CNS), albeit at low levels. Cytokines are involved in virtually every facet of stroke and they have numerous pro-inflammatory and pro-coagulant effects on endothelium. TNF-alpha expression after stroke stimulates expression of tissue factor and adhesion molecules for leukocytes, release of interleukin-1 (IL-1), nitric oxide, factor VIII/von Wi…

medicine.medical_treatmentInflammationProinflammatory cytokineBrain IschemiaBrain ischemiaTissue factorDrug DiscoverymedicineHumansStrokePharmacologyInflammationMicrogliabusiness.industrymedicine.diseasePrognosisStrokeCytokinemedicine.anatomical_structureImmunologyAcute DiseaseCytokinesTumor necrosis factor alphamedicine.symptomStroke cytokinesbusinessBiomarkers
researchProduct